Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029551 | 0.84 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL9900075 | 0.83 | ALDH1A1 (0.68) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL12377859 | 0.81 | HDAC1 (0.58) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL12377852 | 0.81 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL12377853 | 0.77 | HDAC1 (0.54) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL12377866 | 0.75 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL12377865 | 0.75 | RAB9A (0.51) | PDE4BALDH1A1 | |
| SCHEMBL12377867 | 0.75 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL12266902 | 0.74 | RAB9A (0.51) | ALDH1A1 | |
| SCHEMBL24883415 | 0.72 | PPARA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | HSD17B1 241/4885HDAC1 120/4885HDAC8 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.